Stay updated on Anti-CD38 Antibody Trial in CD38+ Malignancies

Sign up to get notified when there's something new on the Anti-CD38 Antibody Trial in CD38+ Malignancies page.
Latest website image capture
Clouds background image

Latest updates to the Anti-CD38 Antibody Trial in CD38+ Malignancies page

  1. Check
    7 days ago
    Change Detected
    Summary
    A banner announces an NIH-wide transition and says federal agencies are using “Super Intelligence” instead of “Artificial Intelligence,” with both terms appearing during the transition.
    Difference
    1%
    Check dated 2026-10-26T13:49:55.000Z thumbnail image
  2. Check
    14 days ago
    Change Detected
    Summary
    The ClinicalTrials.gov footer revision label changes from v3.7.1 to v3.7.2.
    Difference
    0.2%
    Check dated 2026-10-19T13:53:58.000Z thumbnail image
  3. Check
    21 days ago
    Change Detected
    Summary
    The footer revision identifier changes from v3.7.0 to v3.7.1; the page continues to display a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-10-12T14:08:13.000Z thumbnail image
  4. Check
    28 days ago
    Change Detected
    Summary
    The study record page shows a 403 Forbidden message and a Home link instead of study details.
    Difference
    0.5%
    Check dated 2026-10-05T19:00:26.000Z thumbnail image
  5. Check
    42 days ago
    Change Detected
    Summary
    The page now displays a 403 Forbidden error, replacing the normal study details. As a result, users cannot view the NCT01084252 study record or related information.
    Difference
    22%
    Check dated 2026-09-21T20:48:42.000Z thumbnail image
  6. Check
    49 days ago
    Change Detected
    Summary
    The list of recruitment sites was updated to add Tel Litwinsky, Israel and remove Qiryat Krinitzi, Israel.
    Difference
    0.0%
    Check dated 2026-09-14T18:02:37.000Z thumbnail image

Stay in the know with updates to Anti-CD38 Antibody Trial in CD38+ Malignancies

Enter your email address, and we'll notify you when there's something new on the Anti-CD38 Antibody Trial in CD38+ Malignancies page.